AbbVie (NYSE:ABBV) has submitted a supplemental marketing application to the FDA seeking approval of Imbruvica (ibrutinib), combined with Roche’s Rituxan (rituximab), for the first-line treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Related ticker: Johnson & Johnson (NYSE:JNJ)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.